Asthika Goonewardene
Stock Analyst at Truist Financial
(3.04)
# 2,447
Out of 4,547 analysts
322
Total ratings
41.1%
Success rate
2.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $45 → $32 | $28.26 | +12.31% | 5 | Jun 22, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $8.12 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $10 | $1.85 | +440.54% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 | $92.33 | +67.88% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $70 | $23.54 | +197.37% | 10 | Mar 13, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | n/a | $183.29 | - | 9 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $1.65 | +324.24% | 11 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.49 | +60.64% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $24.05 | +66.32% | 4 | Mar 3, 2026 | |
| SEPN Septerna | Maintained: Buy | n/a | $33.68 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $29.48 | +1.76% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.48 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $28.37 | +69.22% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $14.63 | +139.23% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $56.12 | -9.12% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.47 | +446.08% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $23.00 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $130.28 | +11.30% | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $206.84 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.25 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.81 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $15 | $5.11 | n/a | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 268.49 → kr 347.07 | kr 1,860 | n/a | 2 | Jul 14, 2022 |
ArriVent BioPharma
Jun 22, 2026
Reiterated: Buy
Price Target: $45 → $32
Current: $28.26
Upside: +12.31%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.12
Upside: -
Allogene Therapeutics
Mar 13, 2026
Maintained: Buy
Price Target: $10
Current: $1.85
Upside: +440.54%
BioNTech SE
Mar 13, 2026
Maintained: Buy
Price Target: $155
Current: $92.33
Upside: +67.88%
Legend Biotech
Mar 13, 2026
Maintained: Buy
Price Target: $70
Current: $23.54
Upside: +197.37%
Revolution Medicines
Mar 9, 2026
Maintained: Buy
Price Target: n/a
Current: $183.29
Upside: -
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $1.65
Upside: +324.24%
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.49
Upside: +60.64%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $24.05
Upside: +66.32%
Septerna
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $33.68
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $29.48
Upside: +1.76%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $5.48
Upside: -
Feb 25, 2026
Reiterated: Buy
Price Target: $48
Current: $28.37
Upside: +69.22%
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $14.63
Upside: +139.23%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $56.12
Upside: -9.12%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.47
Upside: +446.08%
Nov 11, 2025
Maintained: Buy
Price Target: n/a
Current: $23.00
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $130.28
Upside: +11.30%
Apr 24, 2024
Maintained: Hold
Price Target: n/a
Current: $206.84
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $7.25
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $0.81
Upside: n/a
Aug 23, 2022
Maintained: Buy
Price Target: $19 → $15
Current: $5.11
Upside: n/a
Jul 14, 2022
Maintained: Buy
Price Target: kr 268.49 → kr 347.07
Current: kr 1,860
Upside: n/a